| Sample ID |
BCNU [µM] |
CCNU [µM] |
Procarbazine [µM] |
Temozolomide [mM] |
Cisplatin [µM] |
Cytarabine [µM] |
Methotrexate [mM] |
Irinotecan [µM] |
Topotecan [µM] |
Vincristine [nM] |
| HROG02 |
68.0 |
20.0 |
20.0 |
2.0 |
1.0 |
1.0 |
>1.0 |
0.07 |
0.02 |
2.0 |
| HROG04 |
209.0 |
241.0 |
33.3 |
3.5 |
>30 |
>500 |
>1.0 |
2.0 |
3.0 |
4.0 |
| HROG05 |
110.0 |
137.0 |
35.7 |
1.2 |
4.0 |
0.5 |
>1.0 |
0.6 |
0.02 |
0.3 |
| HROG06 |
111.8 |
98.3 |
37.2 |
0.5 |
10.0 |
500 |
>1.0 |
0.07 |
0.1 |
18.0 |
| HROG07 |
279.0 |
359.0 |
38.7 |
2.0 |
>30 |
>500 |
>1.0 |
28.0 |
1.5 |
244 |
| HROG10 |
158.0 |
101.0 |
25.0 |
1.5 |
16.3 |
>500 |
>1.0 |
65.5 |
1.2 |
244 |
| HROG13 |
312.0 |
198.0 |
34.4 |
2.0 |
12.0 |
>500 |
>1.0 |
58.8 |
1.2 |
200 |
| HROG15 |
52.0 |
101.0 |
35.7 |
0.8 |
7.0 |
3.7 |
>1.0 |
0.07 |
0.02 |
3.6 |
| HROG17 |
21.3 |
61.0 |
3.8 |
0.05 |
3.2 |
0.1 |
>1.0 |
0.07 |
0.01 |
1.4 |
| HROG24 |
28.3 |
21.8 |
30.1 |
0.2 |
1.3 |
3.8 |
>1.0 |
0.03 |
0.02 |
9.0 |
| HROG36 |
46.0 |
27.5 |
31.6 |
1.2 |
3.2 |
0.5 |
>1.0 |
0.1 |
0.01 |
1.8 |
| HROG38 |
136.6 |
237.4 |
32.6 |
1.0 |
17.0 |
32.0 |
>1.0 |
0.8 |
1.0 |
1.8 |
Calculated IC50 values (from three independent assessments in triplicates) for 144
hour incubation periods with the therapeutic agents are provided for all cell lines |
